[
  {
    "ts": null,
    "headline": "The Smartest Dividend Stocks to Buy With $1,000 Right Now",
    "summary": "Here are three dividend stocks to consider for your long-term portfolio.  If you're about to yawn at the thought of a huge telecommunications company, stop -- and check out AT&T's (NYSE: T) recent dividend yield: 4.9%.  AT&T has recently sold off its 70% stake in DirecTV, generating a lot of cash that can be used to pay down debt and to reward shareholders.",
    "url": "https://finnhub.io/api/news?id=3c6ea6deb0a9a453672be2de0b036f2a665b44b868a0868d4d5ec85e674a2f52",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1735209300,
      "headline": "The Smartest Dividend Stocks to Buy With $1,000 Right Now",
      "id": 132164109,
      "image": "https://g.foolcdn.com/editorial/images/802040/getty-pointing-to-cash-fanned-out-in-hand.jpg",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "Here are three dividend stocks to consider for your long-term portfolio.  If you're about to yawn at the thought of a huge telecommunications company, stop -- and check out AT&T's (NYSE: T) recent dividend yield: 4.9%.  AT&T has recently sold off its 70% stake in DirecTV, generating a lot of cash that can be used to pay down debt and to reward shareholders.",
      "url": "https://finnhub.io/api/news?id=3c6ea6deb0a9a453672be2de0b036f2a665b44b868a0868d4d5ec85e674a2f52"
    }
  },
  {
    "ts": null,
    "headline": "PJP: Big Pharma Concentration Risks Amid Looming Confirmation Of RFK Jr.",
    "summary": "This article discusses the risk and opportunities of six major constituents of PJP ETF: Pfizer, Amgen, Gilead, AbbVie, BMY, and Merck. Read more here.",
    "url": "https://finnhub.io/api/news?id=d9924bfb15be4a412c5d30ffc3c153fb65db609d6f0526759c3ece67141e5e6e",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1735205436,
      "headline": "PJP: Big Pharma Concentration Risks Amid Looming Confirmation Of RFK Jr.",
      "id": 132164310,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/832255342/image_832255342.jpg?io=getty-c-w1536",
      "related": "ABBV",
      "source": "SeekingAlpha",
      "summary": "This article discusses the risk and opportunities of six major constituents of PJP ETF: Pfizer, Amgen, Gilead, AbbVie, BMY, and Merck. Read more here.",
      "url": "https://finnhub.io/api/news?id=d9924bfb15be4a412c5d30ffc3c153fb65db609d6f0526759c3ece67141e5e6e"
    }
  },
  {
    "ts": null,
    "headline": "Aldeyra Therapeutics: Key Inflection Point Ahead",
    "summary": "Aldeyra Therapeutics is finally nearing commercialization, attracting renewed attention from some analyst firms. Explore more details here.",
    "url": "https://finnhub.io/api/news?id=10af05bf9f0688c770c57908279186db85d87deaaca66dd3db48c19f3191eea5",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1735185846,
      "headline": "Aldeyra Therapeutics: Key Inflection Point Ahead",
      "id": 132162355,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1281832252/image_1281832252.jpg?io=getty-c-w1536",
      "related": "ABBV",
      "source": "SeekingAlpha",
      "summary": "Aldeyra Therapeutics is finally nearing commercialization, attracting renewed attention from some analyst firms. Explore more details here.",
      "url": "https://finnhub.io/api/news?id=10af05bf9f0688c770c57908279186db85d87deaaca66dd3db48c19f3191eea5"
    }
  }
]